Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10549-021-06383-5.pdf
Reference100 articles.
1. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233–247. https://doi.org/10.1146/annurev-med-070909-182917
2. Nardone A, De Angelis C, Trivedi M V, Osborne CK, Schiff R (2015) The changing role of ER in endocrine resistance. Breast. 24Suppl 2(02):S60–S66. https://doi.org/10.1016/j.breast.2015.07.015
3. American Cancer Society. Breast Cancer Facts & Figures 2019–2020. Am Cancer Soc Inc. 2019
4. Buzdar AU (2004) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol Off J Am Soc Clin Oncol 22(15):3199
5. Ballinger TJ, Meier JB, Jansen VM (2018) Current landscape of targeted therapies for hormone-receptor positive, HER2 negative metastatic breast cancer. Front Oncol 8:308
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer;BMC Medicine;2024-01-12
2. Current Management and Future Perspectives of Hormone Receptor–Positive HER2-Negative Advanced Breast Cancer;Seminars in Oncology Nursing;2023-12
3. Determinants of response to CDK4/6 inhibitors in the real-world setting;npj Precision Oncology;2023-09-13
4. Coencapsulation of Gemcitabine and Thymoquinone in Citrem–Phosphatidylcholine Hexosome Nanocarriers Improves In Vitro Cellular Uptake in Breast Cancer Cells;Molecular Pharmaceutics;2023-08-16
5. Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy;JAMA Network Open;2023-05-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3